Avoid Clinical Inertia in Patients With HFrEF and CKD
September 2022
Few patients with chronic kidney disease (CKD) are on optimized meds for heart failure with reduced ejection fraction (HFrEF).
It’s a delicate balance. Hyperkalemia can occur with an ACEI or ARB, Entresto (sacubitril/valsartan), or an aldosterone antagonist.
Plus these meds or SGLT2 inhibitors (Farxiga, etc) can cause an initial bump in serum creatinine (SCr).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote